 |
70 Diseases |  |
70 Trials |
|
70 Trials |  |
2588 News |  |
| «12...2021222324252627282930...5354» |
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Dizziness In Stroke: Triage Nurses Identify Posterior Circulation Strokes In A Comprehensive Stroke Center Emergency Department Using Three Simple Questions (Riverside Room R02-R05) - Dec 21, 2021 - Abstract #ISC2022ISC_5;
Data were retrospectively reviewed on patients who presented with dizziness, were diagnosed with posterior circulation strokes, and received IV Alteplase... A triage nurse three-question dizziness tool is successful and sustainable in identifying posterior circulation strokes in the emergency department which helps to decrease DTN times in these patients.
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Accuracy Of Patient-Reported Body Weight On A Mobile Stroke Unit Compared To Measured Body Weight And Alteplase Dosing Implications (Hall B2, Poster Hall; Board No. P4) - Dec 21, 2021 - Abstract #ISC2022ISC_1;
Within our single-center cohort, patient-reported weights were an accurate surrogate for measured patient weights for administration of IV tPA in the prehospital MSU setting. However, patient-reported weights may increase dosing errors which could have both efficacy and safety implications.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Association between pre-treatment perfusion profile and cerebral edema after reperfusion therapies in ischemic stroke. (Pubmed Central) - Dec 21, 2021
The effect of reperfusion on edema may be variable and dependent on the physiological state of the cerebral tissue. In patients with small to moderate ischemic core volume, the benefit of reperfusion in reducing edema is related to penumbral salvage.
- verapamil / Generic mfg., brimonidine tartrate / Generic mfg.
ACUTE MONOCULAR VISUAL LOSS AFTER SINUS SURGERY. (Studio 105 (Sunset Center)) - Dec 20, 2021 - Abstract #WSMRF2022WSMRF_633;
In conclusion, we highlight the combination of retinal ischemic features on fundoscopy and proximal ON diffusion restriction on MR-DWI to be diagnostic of proximal CRAO. Future studies should evaluate the accuracy and utility of MR-DWI and HBO in acute CRAO.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Review, Journal: Differences between surviving and non-surviving venous thromboembolism COVID-19 patients: a systematic review. (Pubmed Central) - Dec 17, 2021
Unfractionated and low-molecular-weight heparin drove parenteral anticoagulation and alteplase the advanced treatment in both groups. The original Pulmonary Embolism Severity Index could be helpful in the risk stratification.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Using lysis therapy to treat five critically ill COVID-19 patients who show echocardiographic criteria of right ventricular strain. (Pubmed Central) - Dec 16, 2021
This therapeutic intervention yielded an immediate favorable outcome on follow up and all five patients were extubated and transferred to the ward. This report suggests that bedside echocardiography can be a beneficial tool in the urgent assessment of the right ventricle-to-pulmonary vascular coupling in mechanically ventilated COVID-19 patients, and thrombolytic therapy may be beneficial in hemodynamically unstable patients who show echocardiographic criteria of right ventricular strain.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. (Pubmed Central) - Dec 16, 2021
This report suggests that bedside echocardiography can be a beneficial tool in the urgent assessment of the right ventricle-to-pulmonary vascular coupling in mechanically ventilated COVID-19 patients, and thrombolytic therapy may be beneficial in hemodynamically unstable patients who show echocardiographic criteria of right ventricular strain. No abstract available
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Early NT-ProBNP (N-Terminal Probrain Natriuretic Peptide) Elevation Predicts Malignant Edema and Death After Reperfusion Therapy in Acute Ischemic Stroke Patients. (Pubmed Central) - Dec 16, 2021
No abstract available An early increase in NT-proBNP levels was related to malignant edema and stroke mortality after reperfusion therapy.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Diffusion-Weighted Imaging Lesions After Intracerebral Hemorrhage and Risk of Stroke: A MISTIE III and ATACH-2 Analysis. (Pubmed Central) - Dec 16, 2021
In a heterogeneous cohort of patients with ICH, presence of a DWI lesion was associated with a 2.5-fold heightened risk of stroke among ICH survivors. This elevated risk persisted for ischemic stroke but not for recurrent ICH.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Tenecteplase for Acute Ischemic Stroke Treatment. (Pubmed Central) - Dec 16, 2021
Further phase 3 studies are in progress comparing rt-PA with TNK for acute ischemic stroke during the first 4.5 hours. Studies are also in progress to evaluate the use of TNK for extended applications, such as wake-up stroke.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Alteplase and Adjuvant Therapies for Acute Ischemic Stroke. (Pubmed Central) - Dec 16, 2021
The future of IV alteplase and the changing standard for treatment of AIS remain unwritten with the increasing evidence for imaging selection for both endovascular thrombectomy and IV alteplase, while novel adjuncts are under investigation. In this article, we review the history of IV alteplase investigations for stroke, evidence for thrombectomy as an adjunct to IV alteplase, and the potential of novel adjuvant therapeutics currently under investigation.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial. (Pubmed Central) - Dec 16, 2021
Catheter patency is related rather to the time interval between sessions and to previous malfunction (thus probably reflecting undefined individual factors). The incidence of CR-BSI within pre-selected haemodialysis population is sporadic (less than 1 per 4.3 patient years in our sample).
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Should Tenecteplase Replace Alteplase for Acute Thrombolysis? (Pubmed Central) - Dec 16, 2021
The incidence of CR-BSI within pre-selected haemodialysis population is sporadic (less than 1 per 4.3 patient years in our sample). No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. (Pubmed Central) - Dec 16, 2021
No abstract available Routine use of tenecteplase for stroke thrombolysis was feasible and had comparable safety profile and outcome to alteplase.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Endovascular Treatment for Acute Ischemic Stroke in Children: Experience From the MR CLEAN Registry. (Pubmed Central) - Dec 16, 2021
EVT of children with acute ischemic stroke seems safe and feasible. However, these findings should be interpreted with caution as more and larger studies are needed to clarify the trade-off between risks and benefits of this treatment.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Involvement of emergency medicine pharmacists in stroke thrombolysis: A cohort study. (Pubmed Central) - Dec 16, 2021
Re-design of the stroke call-out team that included addition of an EM pharmacist was associated with improvements in DTNT. The effect of individual interventions at one point in time could not be demonstrated.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Acute Ischemic Stroke Associated with Myocardial Infarction: Challenges and Management. (Pubmed Central) - Dec 16, 2021
For patients presenting with AIS in the setting of a recent MI, treatment with alteplase, an intravenous tissue plasminogen activator, can be given, provided anterior wall myocardial involvement has been carefully evaluated. It is important for clinicians to recognize that troponin elevations can occur in the setting of AIS as well as other clinical scenarios and that this may have implications for short- and long-term mortality.
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Outcomes of Thrombolytic Therapy of Tunnelled Hemodialysis Catheter Dysfunction. (Pubmed Central) - Dec 16, 2021
This retrospective study included 62 patients with tunneled THC thrombosis treated with alteplase between 2017 and2020 in the study center...The success of thrombolysis in subsequent de novo THC thrombosis decreases in patients who previously required intraluminal thrombolytic administration. Identifying patient subgroups with a high risk for THC thrombosis may be useful to investigate effective secondary prevention strategies.
- || Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Associations of thrombus perviousness derived from entire thrombus segmentation with functional outcome in patients with acute ischemic stroke. (Pubmed Central) - Dec 16, 2021
Thrombus perviousness is strongly associated with functional outcome and intravenous alteplase treatment success in patients with acute ischemic stroke...In the multivariable logistic regression models including age, NIHSS, and recanalization, only TAI measures derived from the entire thrombus were independently associated with favorable outcome; OR of 1.64(95 %CI:1.01-2.66, p = 0.048) for Q2 and 1.82(1.13-2.95, p = 0.014) for MCC per 10 HU increase of thrombus attenuation. The novel perviousness measures of the entire thrombus are more strongly associated with functional outcome than the traditional manual perviousness assessments.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Enrollment change, Trial completion date: TASTEa: Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (clinicaltrials.gov) - Dec 8, 2021
P2, N=104, Completed, Sponsor: Melbourne Health
The novel perviousness measures of the entire thrombus are more strongly associated with functional outcome than the traditional manual perviousness assessments. Recruiting --> Completed | N=80 --> 104 | Trial completion date: Mar 2022 --> Nov 2021
- | Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date: REVISION: Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (clinicaltrials.gov) - Dec 7, 2021
P2, N=1400, Not yet recruiting, Sponsor: University Hospital Tuebingen
Recruiting --> Completed | N=80 --> 104 | Trial completion date: Mar 2022 --> Nov 2021 Initiation date: Oct 2021 --> Mar 2022
- |||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Interview: 🔔 #PaperOfTheMonth A new feature highlighting original research in the field of neurology selected by WSA EiC @gsaposnik #December edition! 👉Iv #alteplase before EVT? Editorial & interview to author Prof Yvo Roos👉https://t.co/mprtiaf5Sv #MrCleanNoIV: https://t.co/rRwshnCUs0 (Twitter) - Dec 7, 2021
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase as an Alternative Agent to Alteplase for the Treatment of Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_4207;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparison of Functional Outcomes in Early versus Delayed Administration of Alteplase for Acute Ischemic Stroke in the Emergency Department ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_4095;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparison of Nicardipine and Labetalol for Time to Alteplase Administration in Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3941;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluation of Alteplase Use for the Treatment of Thrombotic Catheter Occlusion ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3711;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparison of Tenecteplase vs. Alteplase in the Setting of Acute Ischemic Stroke: Comparing Time to Recovery and Time to Administration ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3313;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Impact of 24-Hour Pharmacist Coverage in the Emergency Department on Time to Intravenous Alteplase (IVtPA) Administration in Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3114;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluating the Safety and Efficacy of Intravenous Antihypertensives Prior to the Administration of Alteplase for Acute Ischemic Stroke in a Community Hospital Setting ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_3009;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Safety and Efficacy Following Alteplase Administration in a Mobile Stroke Unit ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2977;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Use of Intravenous Alteplase in Acute Ischemic Stroke in the Presence of Relative Contraindications ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2886;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Utilization of Alteplase in Adult Patients with Acute Ischemic Stroke at a Rural Academic Medical Center ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2871;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Airway Emergencies in Patients Who Received Alteplase for Acute Ischemic Stroke and Were on Angiotensin Converting Enzyme Inhibitors Prior to Admission Case Report ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2518;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Characterization of Systemic Alteplase for Submassive and Massive Pulmonary Embolism at a University Health System ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2206;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluation of Alteplase versus Tenecteplase in the Management of Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2152;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluating the Efficacy and Safety Outcomes Between Tenecteplase and Alteplase for Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1667;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Alteplase in Pulmonary Embolism ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1480;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Medication Use Evaluation of Alteplase for Acute Ischemic Stroke at a Large Academic Health System ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1397;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Analysis of Blood Pressure Management Post-Alteplase Administration for Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1163;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Dosing of Alteplase in a Patient with Bilateral Leg Amputation ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1148;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Alteplase Dosing Strategies for Acute Massive and Sub-massive Pulmonary Embolism in the Emergency Department ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_1093;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Intraluminal Alteplase Dosage and Efficacy for Clearing Occluded Central Catheters ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_949;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluation of Guideline Adherence and Clinical Efficacy of Alteplase for Occluded Central Venous Access Devices (CVAD) ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_821;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparison of Tenecteplase versus Alteplase in the Treatment of Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_755;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Evaluation of Drug Therapy Used to Lower Blood Pressure Prior to Alteplase for Acute Ischemic Stroke at a Large Non-Teaching Hospital ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_747;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Analyzing Racial Distribution of Clinical Trials in Adult African American Patients Who Received Alteplase for Acute Stroke in the Last 25 Years ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_692;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparison of Alteplase vs Tenecteplase on Acute Ischemic Stroke Outcomes ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_628;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparative Safety and Efficacy of Tenecteplase versus Alteplase for Acute Ischemic Stroke ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_478;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective Cohort Comparison of Alteplase vs Tenecteplase as Thrombolytic Therapy for Acute Ischemic Stroke in a Community Hospital ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_243;
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Efficacy of Intraluminal Standard Alteplase Dosing for Clearance of Occlusions in Central Venous Catheters in a Primary Acute Care Facility ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_188;